Replies to post #1412 on NightHawk Biosciences Inc (NHWK)

[hschlauch]

Different vaccine, same concept, but with a checkpoint inhibitor included. I have seen someone on here post about the phase I lung cancer trial observing 25% complete response rate - there is absolutely no evidence in the abstract that those responses were complete regressions.

I think to compete against BCG in NMIBC it would likely take several years to really observe statistically significant differences between the arms. BCG trials have observed 1-yr recurrence free rates in the 80%-83% range, so it would have been very difficult to improve statistically upon those rates with HTBX's vaccine at one year out. The differences, in my opinion, would be observed several years after surgical removal when the different arms' would be challenged by new cancer cells.